Genetic GENE Stock
Genetic Price Chart
Genetic GENE Financial and Trading Overview
Genetic stock price | 0.77 USD |
Previous Close | 0.99 USD |
Open | 0.95 USD |
Bid | 0 USD x 1200 |
Ask | 0 USD x 1100 |
Day's Range | 0.95 - 0.99 USD |
52 Week Range | 0.83 - 2.4 USD |
Volume | 66K USD |
Avg. Volume | 128.55K USD |
Market Cap | 23.32M USD |
Beta (5Y Monthly) | 0.560153 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.02 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
GENE Valuation Measures
Enterprise Value | 10.8M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.1706605 |
Price/Book (mrq) | 1.6416667 |
Enterprise Value/Revenue | 1.006 |
Enterprise Value/EBITDA | -1.249 |
Trading Information
Genetic Stock Price History
Beta (5Y Monthly) | 0.560153 |
52-Week Change | -16.10% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.4 USD |
52 Week Low | 0.83 USD |
50-Day Moving Average | 1.01 USD |
200-Day Moving Average | 1.14 USD |
GENE Share Statistics
Avg. Volume (3 month) | 128.55K USD |
Avg. Daily Volume (10-Days) | 61.82K USD |
Shares Outstanding | 19.24M |
Float | 13.09M |
Short Ratio | 1.2 |
% Held by Insiders | 0% |
% Held by Institutions | 6.55% |
Shares Short | 211.17K |
Short % of Float | N/A |
Short % of Shares Outstanding | 1.09% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | -81.088% |
Operating Margin (ttm) | -84.19% |
Gross Margin | 62.45% |
EBITDA Margin | -80.53% |
Management Effectiveness
Return on Assets (ttm) | -29.56% |
Return on Equity (ttm) | -57.15% |
Income Statement
Revenue (ttm) | 10.74M USD |
Revenue Per Share (ttm) | 0.6 USD |
Quarterly Revenue Growth (yoy) | 44.10% |
Gross Profit (ttm) | 6.2M USD |
EBITDA | -8650729 USD |
Net Income Avi to Common (ttm) | -8709925 USD |
Diluted EPS (ttm) | -0.4 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 5.05M USD |
Total Cash Per Share (mrq) | 0.33 USD |
Total Debt (mrq) | 612.39K USD |
Total Debt/Equity (mrq) | 5.55 USD |
Current Ratio (mrq) | 2.08 |
Book Value Per Share (mrq) | 0.6 |
Cash Flow Statement
Operating Cash Flow (ttm) | -7654500 USD |
Levered Free Cash Flow (ttm) | -3807009 USD |
Profile of Genetic
Country | United States |
State | VIC |
City | Fitzroy |
Address | 60-66 Hanover Street |
ZIP | 3065 |
Phone | 61 3 8412 7000 |
Website | https://genetype.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 52 |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Q&A For Genetic Stock
What is a current GENE stock price?
Genetic GENE stock price today per share is 0.77 USD.
How to purchase Genetic stock?
You can buy GENE shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genetic?
The stock symbol or ticker of Genetic is GENE.
Which industry does the Genetic company belong to?
The Genetic industry is Diagnostics & Research.
How many shares does Genetic have in circulation?
The max supply of Genetic shares is 4.85M.
What is Genetic Price to Earnings Ratio (PE Ratio)?
Genetic PE Ratio is now.
What was Genetic earnings per share over the trailing 12 months (TTM)?
Genetic EPS is -0.02 USD over the trailing 12 months.
Which sector does the Genetic company belong to?
The Genetic sector is Healthcare.
Genetic GENE included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Composite Total Return I XCMP | 19079.55 USD — |
-5.82
|
— — | 19064.73 USD — | 19740.96 USD — | — - | — — |
NASDAQ Capital Market Composite RCMP | 92.16 USD — |
-4.45
|
— — | 89.57 USD — | 93.85 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}